Neuphoria Therapeutics
NEUP
15 hedge funds and large institutions have $2.3M invested in Neuphoria Therapeutics in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
82% more capital invested
Capital invested by funds: $1.26M → $2.3M (+$1.04M)
67% more funds holding
Funds holding: 9 → 15 (+6)
0.92% more ownership
Funds ownership: 9.47% → 10.39% (+0.92%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$199K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$195K |
| 3 |
Millennium Management
New York
|
+$170K |
| 4 |
Jane Street
New York
|
+$145K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$325K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$85.1K |
| 4 |
CWP
Cyndeo Wealth Partners
St. Petersburg,
Florida
|
-$71K |
NEUP Hedge Fund Activity: Q3 2025 in Review
15 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q3 2025, worth a combined $2.3M — up 82% from $1.26M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NEUP positions and 3 closed out — a net gain of 6 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Diadema Partners, opening a new position worth an estimated $199K. The largest seller was Lynx1 Capital Management, exiting entirely with an estimated $325K sold.
- 15 institutional investors held Neuphoria Therapeutics (NEUP) as of Q3 2025, up from 9 in Q2 2025.
- Funds reported $2.3M of Neuphoria Therapeutics stock for Q3 2025, up 82% quarter-over-quarter.
- 9 funds opened new Neuphoria Therapeutics positions in Q3 2025 and 3 closed out, a net change of +6 holders.
- The largest Neuphoria Therapeutics buyer in Q3 2025 was Diadema Partners, an estimated $199K added.
- The largest Neuphoria Therapeutics seller in Q3 2025 was Lynx1 Capital Management, an estimated $325K sold.
Based on aggregated 13F filings for Q3 2025.